CETABEN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H39NO2
Molecular Weight	361.5613
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCCNC1=CC=C(C=C1)C(O)=O

InChI

InChIKey=QXWKHSSBFQDQPR-UHFFFAOYSA-N

InChI=1S/C23H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-24-22-18-16-21(17-19-22)23(25)26/h16-19,24H,2-15,20H2,1H3,(H,25,26)

HIDE SMILES / InChI

Molecular Formula	C23H39NO2
Molecular Weight	361.5613
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8005353 | https://www.ncbi.nlm.nih.gov/pubmed/8021805 | https://www.ncbi.nlm.nih.gov/pubmed/313437 | https://www.ncbi.nlm.nih.gov/pubmed/6604816

Cetaben has been identified as an anti-atherosclerotic hypolipidaemic substance. Cetaben is a unique, PPARα-independent peroxisome proliferator with hypolipidemic activity that inhibits cholesterol synthesis in the human hepatoma Hep-G2 cells resulting in reversible changes in Golgi morphology. Cetaben represents an exceptional type of peroxisome proliferator, specifically affecting peroxisomes, without having a negative influence on the processes of peroxisome biogenesis. Cetaben raised only the peroxisomal enzymes, acyl-CoA oxidase, glycerone-phosphate acyltransferase, D-amino-acid oxidase, catalase, and urate oxidase. Cetaben sodium has being shown to be an antiatherosclerotic agent.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Acyl coenzyme A:cholesterol acyltransferase 1 15 Target ID: CHEMBL285 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6985202 \| https://www.ncbi.nlm.nih.gov/pubmed/6604816	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Atherosclerosis 74 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2077185 https://www.ncbi.nlm.nih.gov/pubmed/6606240 https://www.ncbi.nlm.nih.gov/pubmed/6604004	Primary		Preclinical	Unknown Approved Use Unknown
Hyperlipidemia 80 Sources: http://adisinsight.springer.com/drugs/800004625	Primary		Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	1669AH	https://aksci.com/item_detail.php?cat=1669AH
Alfa Chemistry	ACM55986431	http://www.alfa-chemistry.com/search.aspx?q=ACM55986431
ApexBio Technology	C5151	https://www.apexbt.com/catalogsearch/result/?q=C5151
Cayman Chemical	10007171	http://www.caymanchem.com/app/template/Product.vm/catalog/10007171
Chem Scene	CS-0078843	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0078843
MedChem Express	HY-119964	https://www.medchemexpress.com/search.html?q=HY-119964&ft=&fa=&fp=
MolPort	MolPort-003-666-678	https://www.molport.com/shop/molecule-link/MolPort-003-666-678
MuseChem	I005964	https://www.musechem.com/product/I005964.html
Tetrahedron	TS79610	http://www.thsci.com/search.do?q=TS79610
eMolecules	10480628	https://orderbb.emolecules.com/search/#?query=10480628
eNovation Chemicals	D371912	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D371912&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-5232304594	https://mcule.com/MCULE-5232304594/

PubMed

Title	Date	PubMed
Cetaben versus clofibrate: comparison of toxicity and peroxisome proliferation in rats.	1983 Nov	6606240

Patents

Sample Use Guides

In Vivo Use Guide

The effects of cetaben and clofibric acid were compared on the activities of peroxisomal enzymes in the liver and kidney of male Wistar rats. Cetaben at 200 mg/kg body wt increased the activities of all of the enzymes in the liver. The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg.

Route of Administration: Oral

In Vitro Use Guide

The activity of the peroxisomal bifunctional enzyme was not affected in HepG2 cells by clofibric acid and cetaben, whereas the mRNA level was elevated to 2.3 fold by 10 umol/l cetaben. At high concentrations of cetaben all enzyme activities were decreased in both cell lines due to its high cytotoxicity.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:59:50 GMT 2023` Edited by `admin` on `Fri Dec 15 15:59:50 GMT 2023`
Record UNII	DTL5W0113X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CETABEN

Official Name

English

BENZOIC ACID, 4-(HEXADECYLAMINO)-

Common Name

English

P-(HEXADECYLAMINO)BENZOATE

Common Name

English

cetaben [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29703